Bicara Therapeutics (NASDAQ:BCAX) Stock Gets Price Target Trim from HC Wainwright

Bicara Therapeutics (NASDAQ:BCAX – Free Report) had its price objective cut by HC Wainwright from $42.00 to $36.00 in a research note published on Wednesday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Bicara Therapeutics’ Q4 2026 earnings at ($1.07) EPS, FY2026 earnings at ($3.86) EPS, Q1 2027 earnings at ($1.11) EPS, Q2 2027 earnings at ($1.14) EPS, Q3 2027 earnings at ($1.17) EPS, Q4 2027 earnings at ($1.21) EPS and FY2027 earnings at ($4.63) EPS.

A number of other research analysts have also weighed in on BCAX. Stifel Nicolaus reduced their price objective on Bicara Therapeutics from $45.00 to $43.00 and set a “buy” rating for the company in a research report on Tuesday. Wells Fargo & Company lifted their price objective on Bicara Therapeutics from $16.00 to $23.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 12th. Citigroup reissued a “market outperform” rating on shares of Bicara Therapeutics in a report on Tuesday. The Goldman Sachs Group cut Bicara Therapeutics from a “neutral” rating to a “sell” rating and cut their target price for the stock from $20.00 to $8.00 in a research note on Friday, October 30th. Finally, Wall Street Zen cut Bicara Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Bicara Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $30.33.

View Our Latest Analysis on Bicara Therapeutics

Bicara Therapeutics Stock Performance

Shares of BCAX opened at $10.02 on Wednesday. Bicara Therapeutics has a fifty-two week low of $7.87 and a fifty-two week high of $30.99. The firm’s 50-day simple moving average is $16.84 and its two-hundred day simple moving average is $20.78.

Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.22). As a group, equities analysts expect that Bicara Therapeutics will post -3.82 earnings per share for the current fiscal year.

Insider Buying and Selling at Bicara Therapeutics

In other news, CEO Ryan Cohlhepp sold 17,500 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $22.90, for a total transaction of $400,750.00. Following the transaction, the chief executive officer directly owned 181,641 shares of the company’s stock, valued at $4,159,578.90. This represents a 8.79% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.80% of the stock is owned by insiders.

Institutional Trading of Bicara Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Jupiter Topco LLC bought a new stake in shares of Bicara Therapeutics during the 2nd quarter valued at about $93,957,000. Bank of America Corp DE purchased a new stake in shares of Bicara Therapeutics during the 2nd quarter valued at about $10,478,000. Palo Alto Investors LP bought a new position in shares of Bicara Therapeutics in the 2nd quarter worth approximately $16,341,614. Walleye Capital LLC bought a new position in shares of Bicara Therapeutics in the 2nd quarter worth approximately $10,487,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Bicara Therapeutics by 166.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 109,261 shares of the company’s stock worth $2,170,000 after purchasing an additional 68,327 shares during the period.

Bicara Therapeutics News Roundup

Here’s some of the latest news about BCAX:

  • Positive Sentiment: HC Wainwright maintained a Buy rating and a $36 price target. Bicara Therapeutics analyst estimates
  • Neutral Sentiment: HC Wainwright expects Bicara to remain loss-making, estimating a $3.86 per-share loss for FY2026 and $4.63 for FY2027. The FY2026 forecast is close to the cited consensus estimate of a $3.82 loss; the reports do not identify a new clinical or business catalyst.
  • Negative Sentiment: Stifel Nicolaus and Morgan Stanley reportedly cut their BCAX price targets, while BTIG Research issued a pessimistic forecast. The headlines provide no revised target figures, but the downgrades in price expectations may weigh on sentiment. Stifel target cut Morgan Stanley target cut BTIG forecast

About Bicara Therapeutics

(Get Free Report)

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses. The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.

Further Reading

Analyst Recommendations for Bicara Therapeutics (NASDAQ:BCAX)

Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.